Infectious coryza (IC), caused by the bacterium Avibacterium paragallinarum (AP), has historically been a significant burden in tropical and subtropical regions. However, a recent and alarming shift in its geographical footprint has seen it re-emerge as a major threat in northern latitudes, including Europe and North America. In a comprehensive review authored by Mohamed El-Gazzar, Rodrigo Gallardo, Robert Bragg, and colleagues, published in Avian Diseases (DOI:
10.1637/aviandiseases-D-24-00105), the authors synthesize decades of established knowledge with the latest scientific breakthroughs to address the "cloud of mystery" that still surrounds this fastidious pathogen.
For producers, the practical impact of IC is immediate and severe, particularly in egg-laying operations where drops in production can reach 40%. In broilers, the disease leads to growth retardation and increased condemnations at processing due to airsacculitis. The primary clinical indicators—a sharp decline in water and feed intake, facial swelling, and nasal discharge—serve as urgent signals for intervention. Successful management relies on a dual strategy of strict biosecurity and targeted vaccination, as the review highlights that vaccines alone cannot eliminate the challenge in highly contaminated environments.
From a technical perspective, the research emphasizes the critical role of horizontal transmission, particularly through "chronic carrier" birds that shed the bacteria without showing clinical signs. Recent outbreaks in the United States have been directly linked to the movement of these carrier replacement flocks across state lines. This underscores the need for professionals to prioritize the quarantine and testing of new bird introductions. Furthermore, the selection of birds for diagnostic sampling is vital; individuals in the early stages of infection harbor a higher bacterial load, significantly increasing the success rate of isolation.
The academic community and key opinion leaders (KOLs) are currently grappling with the taxonomic and diagnostic challenges posed by the Avibacterium genus. The review points to the discovery of nonpathogenic Avibacterium paragallinarum (npAP) and NAD-independent strains as significant hurdles. The latter, which do not require the traditional "nursing colony" (V-factor) for growth, first gained prominence in South Africa and have proven to be highly contagious, complicating routine laboratory identification protocols.
A central point of debate raised in the study is the limitation of current serotyping and vaccination frameworks. While inactivated bacterins are the industry standard, they generally only provide protection within the same serogroup (A, B, or C). Multiple reports now indicate that even within these groups, cross-protection is not always complete, leading to vaccine failures when variant strains emerge. This has sparked a push toward whole-genome sequencing (WGS) and sequence typing as more reliable, affordable alternatives to traditional serological assays.
The review also identifies substantial knowledge gaps in the genomics of AP compared to other avian pathogens. While WGS offers the potential to pinpoint determinants of virulence and antimicrobial resistance, the current database of high-quality sequences is limited to a handful of countries. This lack of diversity in genomic data hinders the development of a universal typing method that can accurately track global outbreaks.
Furthermore, the absence of commercially available, scalable serological assays like ELISA remains a major bottleneck. While PCR and qPCR have improved detection sensitivity, they do not distinguish between active disease and mere presence of the pathogen, nor do they help in evaluating the efficacy of vaccine "take" in a flock. Developing these tools is essential for modernizing surveillance and long-term control strategies.
In conclusion, Avibacterium paragallinarum remains a formidable and evolving adversary for the global poultry industry. As the pathogen adapts to new climates and exhibits genomic plasticity through mobile genetic elements, the industry must transition from traditional, often confusing phenotypic classification to more robust genomic and molecular frameworks to ensure sustainable production.
Given the limitations in cross-protection between traditional serovars and the rise of NAD-independent strains, is it time for the industry to move away from commercial bacterins in favor of farm-specific autogenous vaccines and sequence-based surveillance?